Matinas BioPharma Nanotechnologies, Inc.

This pivotal, confirmatory trial seeks to independently verify the results observed in the EnACT Phase II Stage 2 trial (MB-70007).

Pharmacodynamic effects of MAT9001 compared to Vascepa in adults with hypertriglyceridemia

This is a single-center, open-label, pilot study to evaluate the efficacy of 14 days of CAMB dosing in subjects with fluconazole-resistant vulvovaginal candidiasis (VVC).